Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 16.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter.
Pharming Group Trading Up 6.0 %
Shares of PHAR opened at $9.93 on Wednesday. The firm’s 50 day simple moving average is $8.76 and its 200 day simple moving average is $8.36. Pharming Group has a 1-year low of $6.65 and a 1-year high of $13.20. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The company has a market capitalization of $673.60 million, a P/E ratio of -38.19 and a beta of -0.08.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on PHAR. Jefferies Financial Group started coverage on Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Tuesday, December 17th. Finally, Oppenheimer lowered their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
- Five stocks we like better than Pharming Group
- Insider Trades May Not Tell You What You Think
- 3 Dividend Stocks at Bargain Levels to Defend Your Portfolio
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 REITs With Big Dividend Growth and Sustainable Payouts
- What is a buyback in stocks? A comprehensive guide for investors
- Can Integrated Healthcare Stocks Succeed in Public Markets?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
